The ADSs are listed on the Nasdaq Global Market

Davis Polk advised the sales agent in connection with a new SEC-registered at-the-marketing offering program by Immunocore Holdings plc of its American depositary shares (ADSs) representing its ordinary shares under which Immunocore may sell up to an aggregate amount of $250 million in ADSs. Immunocore’s ADSs are listed on the Nasdaq Global Market under the symbol “IMCR.”

Immunocore is a commercial-stage biotechnology company developing a class of T cell receptor, or TCR, bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune diseases.

The Davis Polk capital markets team included partner Yasin Keshvargar. Partner Simon Witty and associate Vivek Thanki provided English law advice. Partner David R. Bauer provided intellectual property advice. The tax team included partner Jonathan Cooklin, counsel Alon Gurfinkel and associate Freddie Schwier. Members of the Davis Polk team are based in the New York and London offices.